Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results. Daver, N., Vyas, P., Kambhampati, S., Al Malki, M. M., Larson, R. A., Asch, A., Mannis, G. N., Chai-Ho, W., Tanaka, T. N., Bradley, T. J., Jeyakumar, D., Wang, E. S., Xing, G., Chao, M., Ramsingh, G., Renard, C., Lal, I., Zeidner, J. F., Sallman, D. LIPPINCOTT WILLIAMS & WILKINS. 2022

View details for Web of Science ID 000863680301921